-
2024-516966-12-00
4
2026-02-13
Alzheimer’s disease
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2025-521684-12-00
4
2026-01-13
Hidradenitis Suppurativa
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2025-522452-16-00
4
2025-12-05
Endometriosis related pain
-
2024-520206-19-00
5
2025-12-02
Hyperuricemia associated with gout.
-
2025-522347-18-00
4
2025-11-26
Major Depressive Disorder (MDD), with or without Anxious Distress
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2025-521892-30-00
5
2025-11-24
Primary isolated CABG patients with stable coronary artery disease (ch
-
2025-521920-31-00
4
2025-11-21
Graves’ Disease
-
2023-508935-30-00
5
2025-11-20
Lower extremity artery disease
-
2024-516520-34-00
3
2025-11-17
Rheumatoid Arthritis
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2024-520165-32-00
5
2025-11-04
BP-I mania or mania with mixed features
-
2024-519270-40-00
5
2025-10-30
Major Depressive Disorder
-
2023-506296-97-00
5
2025-10-28
Moderate to Severe Plaque Psoriasis
-
2024-517184-23-00
4
2025-10-16
platinum-resistant advanced high-grade epithelial ovarian, primary per
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2025-520490-38-00
3
2025-10-13
Haemophilia A with or without inhibitors. Proposed indication under de
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-518714-31-00
5
2025-10-03
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)
-
2024-519736-17-00
4
2025-10-03
Hidradenitis Suppurativa